CD274 and neoplasm: However, also in this study, the interpretation was limited, particularly for males-related information, by a relevant trials’ heterogeneity as well as a difference in cut-offs of biomarkers expression: KEYNOTE 010, KEYNOTE 024, and CHECKMATE 026 trials included PD-L1 tumor-expression positivity as an inclusion criteria, while CHECKMATE 017 and CHECKMATE 057 trials included patients with NSCLC regardless of their PD-L1 status [29].